Biosimilar infliximab for the management of rheumatoid arthritis in France: what are the expected savings?
Fiche publication
Date publication
mars 2017
Journal
European journal of hospital pharmacy. Science and practice
Auteurs
Membres identifiés du Cancéropôle Est :
Pr VELTEN Michel
Tous les auteurs :
Beck M, Michel B, Rybarczyk-Vigouret MC, Sordet C, Sibilia J, Velten M
Lien Pubmed
Résumé
Biosimilar infliximab, the first similar biological medicinal product containing monoclonal antibodies to be commercialised, is likely to contribute to a significant reduction in healthcare costs. We aimed to assess the cost savings potential over 1 year of the use of biosimilar infliximab for the treatment of rheumatoid arthritis (RA) patients in Alsace and in France, in a real-life setting.
Mots clés
France, biosimilar, cost, infliximab, real-life setting, rheumatoid arthritis
Référence
Eur J Hosp Pharm Sci Pract. 2017 Mar;24(2):85-90